Prosecution Insights
Last updated: July 17, 2026
Application No. 17/996,372

IMAGE GENERATION DEVICE, DISPLAY DEVICE, DATA CONVERSION DEVICE, IMAGE GENERATION METHOD, PRESENTATION METHOD, DATA CONVERSION METHOD, AND PROGRAM

Non-Final OA §101§102
Filed
Oct 17, 2022
Priority
Apr 21, 2020 — JP 2020-075691 +1 more
Examiner
LIN, JERRY
Art Unit
1685
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kewpie Corporation
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
1m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
605 granted / 837 resolved
+12.3% vs TC avg
Moderate +15% lift
Without
With
+15.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
24 currently pending
Career history
853
Total Applications
across all art units

Statute-Specific Performance

§101
25.5%
-14.5% vs TC avg
§103
29.2%
-10.8% vs TC avg
§102
15.2%
-24.8% vs TC avg
§112
12.1%
-27.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 837 resolved cases

Office Action

§101 §102
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-10 and 12 are under examination. Priority 2. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Drawings 3. Color photographs and color drawings are not accepted in utility applications unless a petition filed under 37 CFR 1.84(a)(2) is granted. Any such petition must be accompanied by the appropriate fee set forth in 37 CFR 1.17(h), one set of color drawings or color photographs, as appropriate, if submitted via the USPTO patent electronic filing system or three sets of color drawings or color photographs, as appropriate, if not submitted via the via USPTO patent electronic filing system, and, unless already present, an amendment to include the following language as the first paragraph of the brief description of the drawings section of the specification: The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. Color photographs will be accepted if the conditions for accepting color drawings and black and white photographs have been satisfied. See 37 CFR 1.84(b)(2). Claim Interpretation 4. The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Claim Rejections - 35 USC § 101 5. 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-10 and 12 rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception without significantly more. Claims 1-10 and 12 are directed to a method and device for presenting an image. As described in Alice Corp. Pty. Ltd. V. CLS Bank Int’l, 573 U.S._, 134 S. Cr. 2347, 110 U.S.P.Q.2d 1976 (2014), a two-step analysis is required in considering the patent eligibility of the claimed subject matter. The first step requires determining if the claimed subject matter is directed to a judicial exception. The instant claims require the converting expression levels of microRNA into image data in a matrix of two dimensions or more, classifying the image data, and generating an image representing the contribution of a specific part of the image data to the classification. However, creating a graphical image of microRNA expression level can be done mentally with a pen and paper. Mental steps are a judicial exception. Dependent claims 2-5, 9, 10 recite additional mental steps or mathematical algorithm (Levenshtein distance).The courts have found mathematical algorithms to be drawn to the judicial exception of an abstract idea (In re Grams, 888 F.2d 835, 12 U.S.P.Q.2d 1824 (Fed. Cir. 1989)). Thus, the instant claims are drawn to a judicial exception. This judicial exception is not integrated into a practical application. The instant claims do not recite an element that reflects an improvement in the functioning of a computer or other technology, an element that applies the judicial exception to effect a particular treatment, an element that implements the judicial exception with a particular machine, or an element that effects a transformation of a particular article to a different state or thing. The instant claims recite an image generation device and a display unit. However, the instant claims do recite not any structural limitations of the device or display unit. Thus, the instant claims do not recite a particular machine. The instant claims also recite displaying images and acquiring images. These are extra solution data gathering and output steps. Such extra solution steps are not sufficient to integrate the judicial exception into a practical application. The second part of the analysis requires determining if the claims include additional elements that are sufficient to amount to significantly more than the judicial exception. The instant claims recite the additional elements of a device, display unit, acquiring images and displaying images. However, these elements are well-understood, conventional and routine (Specification, pages 32-34). Reciting such well-understood, routine, and conventional elements do not transform a judicial exception into patent eligible subject matter. In addition, the recitation of the specific types of data, to be used in the judicial exception, does not transform the abstract idea into a non-abstract idea. (See buySAFE, Inc. v Google, Inc. 765 F.3d 1350, 112 U.S.P.Q.2d 1093 (Fed.Cir.2014)). Furthermore, the elements taken as a combination are also well-understood, routine, and conventional, since the elements are merely specifying gathering data and a device to implement to judicial exception. Thus, the instant claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception. Claim Rejections - 35 USC § 102 6. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 2, 4-7, and 12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Barry et al. (US 2014/0113978 A1). Regarding claims 1, 6, 7, and 12, Barry et al. disclose a method and device that includes an imaging unit configured to convert data representing an expression level for each microRNA type into image-rendition data serving as data representing a matrix of two dimensions or more (paragraph [0022]); classification unit configured to perform classification of the image-rendition data (paragraph [0131]); and a contribution-presentation-image generation unit configured to generate a contribution-presentation image representing a contribution of a specific part of the image-rendition data to the classification (paragraphs [0022], [0131], and Fig. 8). In addition, Barry et al. teach generating a grounds-presentation image presenting grounds of the classification in a two dimensional image (paragraph [0022], Fig. 8). Furthermore, Barry et al. teach where device includes a display (paragraph [0036]). Regarding claim 2, Barry et al. disclose calculating values of the elements of the matrix representing the image-rendition data based on the expression levels of the microRNA types assigned to the elements of the matrix (paragraph [0022] and Fig. 8). Regarding claim 4, Barry et al. disclose a display unit that displays the contribution-presentation image with a typical contribution-presentation image (paragraph [0022]). Regarding claim 5, Barry et al. disclose where the classification unit classifies the image rendition data in to a healthy class or disease class (paragraph [0131]). Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to JERRY LIN whose telephone number is (571)272-2561. The examiner can normally be reached T-F 7am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Olivia Wise can be reached at (571) 272-2249. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JERRY LIN/Primary Examiner, Art Unit 1685
Read full office action

Prosecution Timeline

Oct 17, 2022
Application Filed
Jun 03, 2026
Non-Final Rejection mailed — §101, §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12680139
CANCER BIOMARKERS
2y 5m to grant Granted Jul 14, 2026
Patent 12676208
TUMOR ANTIGENICITY PROCESSING AND PRESENTATION
4y 5m to grant Granted Jul 07, 2026
Patent 12670971
Bioinformatics Systems, Apparatuses, and Methods Executed on an Integrated Circuit Processing Platform
5y 0m to grant Granted Jun 30, 2026
Patent 12662510
PROTEIN-TARGETED DRUG COMPOUND IDENTIFICATION
5y 10m to grant Granted Jun 23, 2026
Patent 12665053
Genomic Infrastructure for On-Site or Cloud-Based Dna and Rna Processing and Analysis
5y 9m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
87%
With Interview (+15.0%)
3y 11m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 837 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month